MRI contrast developer Epix Medical and MRI-guided high-intensity focused ultrasound firm InSightec have agreed to investigate the use of Epix's MS-325 contrast agent to facilitate the MRI-guided treatment of tumors.
The collaboration will initially focus on preclinical studies to assess the unique properties of MS-325 for MRI guidance of focused ultrasound in normal tissues and in tumors. These preliminary studies may lead to future use in the image-guided therapy program at Brigham and Women's Hospital in Boston, according to Epix of Cambridge, MA, and InSightec of Tirat Carmel, Israel.
By AuntMinnie.com staff writers
March 12, 2001
Related Reading
Epix loss widens in 2000, February 16, 2001
Epix CEO joins board of contrast agent association, February 9, 2001
Copyright © 2001 AuntMinnie.com
